CUMYL-NBMINACA (SGT-152, Cumyl-BC[2.2.1]HpMINACA) is a synthetic cannabinoid compound first reported in a 2013 patent,[1] but not identified as a designer drug until 2021, being identified by a forensic laboratory in Germany in February 2021.[2][3]

See also

References

  1. ^ WO 2014167530, Bowden MJ, Williamson PB, "Cannabinoid compounds", issued 11 April 2013 
  2. ^ Pulver B, Riedel J, Schönberger T, Pütz M, Schäper J, Kunert N, et al. (December 2021). "Comprehensive structural characterisation of the newly emerged synthetic cannabimimetics Cumyl-BC [2.2. 1] HpMeGaClone, Cumyl-BC [2.2. 1] HpMINACA, and Cumyl-BC [2.2. 1] HpMICA featuring a norbornyl methyl side chain". Forensic Chemistry. 26: 100371. doi:10.1016/j.forc.2021.100371. S2CID 243179410.
  3. ^ "New psychoactive substances: 25 years of early warning and response in Europe. An update from the EU Early Warning System" (PDF). June 2022.
Allikas: https://en.wikipedia.org/wiki/CUMYL-NBMINACA
No tags for this post.